Maximum quantity allowed is 999
请选择数量
CAS RN: 38821-49-7 | 產品號碼: C2450
Carbidopa Monohydrate
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | C2450 |
| 純度/分析方法 | >98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__1__0H__1__4N__2O__4·H__2O = 244.25 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Air Sensitive |
| CAS RN | 38821-49-7 |
| 相關CAS RN | 28860-95-9 |
| Reaxys-RN | 4189448 |
| PubChem Substance ID | 125307806 |
| SDBS (AIST Spectral DB) | 52879 |
| MDL編號 | MFCD00889211 |
產品規格
| Appearance | White to Light yellow powder to crystaline |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 %(calcd.on dried substance) |
| Specific rotation [a]20/D | -21.0 ～ -23.5 deg(C=1, AlCl3 sol.) |
| Drying loss | 5.9 to 8.8 % |
性質
| 比旋光 [α]D | -22° (C=1,AlCl3 sol.) |
GHS
相關法規
| RTECS # | MW5300000 |
運輸資料
| HS編碼* | 2928.00-000 |
Application
Carbidopa: A Competitive Inhibitor of Aromatic L-Amino Acid Decarboxylase
Carbidopa is a competitive inhibitor of aromatic L-amino acid decarboxylase. Carbidopa is often used with L-DOPA [D0600] for the treatment of Parkinson's disease. L-DOPA, the metabolic precursor of dopamine [A0305], does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. However, when L-DOPA is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues. Administration of dopamine alone is ineffective in the treatment of Parkinson's disease apparently because dopamine does not cross the blood-brain barrier. Carbidopa inhibits decarboxylation of L-DOPA. Since its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with levodopa makes more L-DOPA available for transport to the brain. Carbidopa does not cross the blood-brain barrier and does not affect the metabolism of L-DOPA within the central nervous system. (The product is for research purpose only.)
References
- L-Dopa Therapy Combined with Peripheral Decarboxylase Inhibitor (MK-486) in Parkinsonism
- Metabolism of Carbidopa [L-(-)-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic Acid Monohydrate], an Aromatic Amino Acid Decarboxylase Inhibitor, in the Rat, Dog, Rhesus Monkey, and Man
- Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of Parkinsonism
- Treatment of Parkinson's disease in the advanced stage (a review)
- Automated determination of levodopa and carbidopa in plasma by high-performance liquid chromatography-electrochemical detection using an online flow injection analysis sample pretreatment unit
- Quantitative analysis of levodopa, carbidopa and methyldopa in human plasma samples using HPLC-DAD combined with second-order calibration based on alternating trilinear decomposition algorithm
考研文獻
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。